Precision oncology, which is the molecular profiling of malignancies to find modifiable changes, is evolving quickly and has become a key element of therapeutic treatment.
Delivering high-quality tissue samples to high-quality laboratories, where proper next-generation sequencing (NGS) molecular analysis produces data that can be put to use, requires the cooperation of many parties.
Undoubtedly, it represents a novel approach to the most effective treatment of cancer.